The central challenge the researchers set out to address is deceptively simple: when a patient is diagnosed with gastric cancer that appears advanced on scans, how reliable is that initial assessment, and what does it actually predict for survival? In Japan, where many tumors that look advanced on imaging turn out to be early-stage disease obscured by inflammatory changes, clinicians have long struggled to identify which patients genuinely benefit from neoadjuvant chemotherapy, or chemotherapy given before surgery. Traditionally, decisions about postoperative chemotherapy have rested on pathological staging, the detailed examination of the removed tumor and lymph nodes. But that approach requires surgery first, leaving no opportunity to shrink the tumor beforehand. With evidence accumulating that perioperative chemotherapy improves survival in resectable advanced disease, the need for trustworthy clinical staging, performed entirely before the operating room, has become urgent.

JCOG1302A was designed as a prospective, multicenter observational study to test exactly how well endoscopy and computed tomography could classify tumor depth and nodal spread. Between July 2013 and November 2014, 1,275 patients were enrolled across 53 specialized Japanese institutions. Each underwent staging with multidetector-row CT using prespecified imaging criteria: localized wall thickening with a smooth serosal surface indicated T2 disease, diffuse thickening with a smooth surface indicated T3, and irregular or nodular serosal change or invasion of surrounding fat signaled T4a, while loss of the fat plane between tumor and adjacent organs defined T4b. Lymph nodes with a short axis of at least 8 millimeters or a long axis of at least 10 millimeters were called metastatic. The earlier analysis found that a striking share of patients clinically labeled T2 or T3 without nodal involvement actually harbored pathologically Stage I disease, contamination that ranged from 50.4 percent in cT2N0 down to just 3.0 percent in cT4aN(+).

That earlier work led the investigators to conclude that patients with clinical T3 disease plus detectable nodes, and those with any T4 disease, were the optimal candidates for preoperative chemotherapy, a conclusion that directly shaped the ongoing Phase III trial JCOG1509. But a critical piece was missing: no study had ever described long-term survival stratified by prospectively determined clinical stage. The new follow-up analysis, JCOG1302A2, collected additional survival data on the original cohort. After excluding patients who did not undergo surgery, those found ineligible, and 83 patients lost to follow-up, 1,176 patients formed the analytical population. The group was overwhelmingly treated with the Japanese standard of gastrectomy plus D2 lymph node dissection, performed in 98 percent of patients, and roughly half received adjuvant chemotherapy, most commonly the oral agent S-1 alone.

The survival data revealed a clean, stepwise gradient across both clinical dimensions. Five-year overall survival was 82.1 percent for clinical T2 tumors, 72.7 percent for T3, 60.0 percent for T4a, and 40.0 percent for the small T4b group. Nodal status told a parallel story: 78.0 percent for node-negative disease, 70.6 percent for cN1, 59.1 percent for cN2, and 28.4 percent for cN3. In statistical models measuring the risk of death over time, clinical T4a carried nearly two and a half times the mortality hazard of T2, while cN3 disease carried almost five times the hazard of cN0. When both dimensions were combined, the picture sharpened further. The most favorable group, comprising cT2N0, cT2N(+), and cT3N0, all achieved five-year survival near or above 77 percent, with cT2N0 topping the chart at 83.5 percent.

Perhaps the most consequential finding concerns the middle of the distribution. Patients with cT3N(+) disease and those with cT4aN0 disease showed nearly identical, intermediate survival, around 68.0 and 66.8 percent at five years respectively, and both carried roughly double the mortality risk of the cT2N0 reference group. Meanwhile, cT4aN(+) patients fared worst among the sizable subgroups, at 57.7 percent. Notably, cT3N0 disease did not show a statistically significant increase in risk compared with cT2N0, suggesting that node-negative T3 tumors, at least when staged by rigorous CT criteria, behave more like earlier disease than like truly advanced cancer. This three-tier risk architecture, favorable, intermediate, and poor, gives clinicians a practical framework for matching treatment intensity to genuine baseline risk.

The results also carry a pointed message about the TNM staging system itself. In the eighth edition of the TNM classification, clinical T3 and T4a tumors are grouped together, despite the acknowledged difficulty of distinguishing them on imaging. The Japanese data, with clearly separated survival curves between the two categories, suggest this merging may obscure clinically meaningful differences. The finding echoes the exploratory radiological sub-analysis of the PRODIGY trial, in which clinical T4 disease, with minimal contamination by pathological Stage I, was identified as the subgroup deriving the greatest benefit from neoadjuvant chemotherapy. Together, these results argue that T3 and T4a disease, when carefully distinguished by multidetector CT, warrant separate consideration in treatment planning and in the design of future clinical trials.

The study’s authors are careful to frame the work as prognostic rather than therapeutic. Because the analysis was observational, it did not directly test whether neoadjuvant chemotherapy improves survival in any subgroup, and the choice and regimen of postoperative chemotherapy were left to treating physicians, varying across patients and institutions. Most patients with Stage III disease received S-1 monotherapy, since the JACCRO GC-07 trial demonstrating the superiority of adding docetaxel had not yet reported when the cohort was treated. Adjuvant chemotherapy use also differed across clinical subgroups, from 34.5 percent in cT2N0 to 65.1 percent in cT4aN(+), a variation that may have influenced the observed outcomes. The cohort excluded scirrhous tumors, bulky nodal disease, and paraaortic metastases, so the findings cannot be generalized to those populations, and all patients were treated at specialized Japanese centers.

Even with those caveats, the timing of this evidence is significant. The Pan-Asian adapted ESMO Clinical Practice Guidelines now emphasize that perioperative chemotherapy should be considered only for selected patients with resectable locally advanced gastric cancer, and the recent MATTERHORN trial has shown that perioperative chemo-immunotherapy can improve outcomes, albeit with greater toxicity and cost. Against that backdrop, knowing which clinically defined groups face the highest baseline mortality risk, and which do well with surgery and standard adjuvant therapy alone, becomes essential for balancing benefit against burden. The data suggest that patients with cT2N0 and cT3N0 disease, who achieved roughly 80 percent five-year survival with upfront surgery, may have little to gain from intensified perioperative regimens, while those with cT3N(+), cT4aN0, cT4aN(+), and cT4b disease represent the higher-risk subgroups in whom such strategies deserve priority investigation.

For a disease that remains one of the world’s leading causes of cancer death, the study delivers something the field has lacked: a prospectively validated, clinically applicable survival map drawn entirely from information available before treatment. It validates the diagnostic criteria used in JCOG1302A, confirms that clinical T and N categories carry genuine prognostic weight, and provides the reference outcomes against which the ongoing JCOG1509 trial and the coming wave of perioperative chemo-immunotherapy studies will be judged. As treatment intensifies, the humble CT scan, applied with disciplined, standardized criteria, may prove to be the most important tool for ensuring that the right patients receive the right therapy at the right time.

Subject of Research: Long-term survival stratified by prospectively determined clinical staging in locally advanced gastric cancer

Article Title: Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow‐Up Study of JCOG1302A

Article References: Hayashi, T., Kato, R., Mitome, N., Ogawa, R., Fukagawa, T., Katai, H., Nunobe, S., Tokunaga, M., Bando, E., Ito, Y., Yamada, T., Nomura, T., Makino, S., Kinoshita, T., Hara, H., Aizawa, M., Boku, N., Kurokawa, Y., Terashima, M., & Yoshikawa, T. (2026). Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow‐Up Study of JCOG1302A. Annals of Gastroenterological Surgery, Article ags3.70293. https://doi.org/10.1002/ags3.70293

Image Credits: AI Generated

DOI: 10.1002/ags3.70293

Keywords: gastric cancer, clinical staging, neoadjuvant chemotherapy, JCOG1302A, overall survival, CT imaging, D2 lymphadenectomy, TNM classification, perioperative treatment, oncology, prognosis, Japan Clinical Oncology Group

The conceptual foundations were laid long before the first camera entered an abdomen. Surgeons such as Kajitani, Okajima, and Maruyama validated D2 lymphadenectomy, the systematic removal of the lymph node stations around the stomach, establishing both the oncologic logic and the therapeutic value of extended nodal dissection. Then came a crucial corrective. Sasako’s landmark randomized trial demonstrated that adding prophylactic para-aortic nodal dissection to D2 surgery did not improve patient survival, a result that shifted the field’s focus toward survival balanced with quality of life and laid the groundwork for the modern, evidence-based approach to deciding how much surgery is enough. That principle, that more extensive is not universally better, now underpins nearly every innovation in the field.

The minimally invasive era began in earnest in 1994, when Kitano reported the first laparoscopic gastrectomy for gastric cancer. Skepticism was intense. Critics questioned whether a two-dimensional video view could ever match the tactile feedback and direct exposure of open surgery, particularly for a cancer operation requiring meticulous lymph node dissection. In 2002, Hashizume performed the first robotic gastrectomy, opening a second technological front. What followed was a systematic, two-decade process of evaluation, refinement, and gradual integration, driven primarily by high-volume centers in Japan, Korea, and China. A single-center pilot study of 164 patients demonstrated the safety of laparoscopic gastrectomy for early gastric cancer and revealed unexpected improvements in postoperative quality of life. A subsequent multicenter phase 2 trial across eight centers extended the approach to more advanced disease, creating the foundation for the definitive randomized trials that would follow.

Those trials have transformed practice. Korea’s KLASS-01 study showed in 2019 that laparoscopic distal gastrectomy was noninferior to open surgery for early gastric cancer in five-year disease-free survival. KLASS-02 extended the finding to locally advanced disease, confirming comparable relapse-free survival with laparoscopic D2 lymphadenectomy and fewer complications. Japan’s JCOG0912 trial established noninferiority for laparoscopy-assisted distal gastrectomy in stage I disease, and the JLSSG0901 trial replicated the result for advanced cancer in 2023. China’s CLASS-01 and CLASS-02 trials contributed complementary evidence for distal and total gastrectomy. Taken together, these studies converted laparoscopic gastrectomy from an experimental technique into an evidence-based standard. Robotic surgery, by contrast, remains at an earlier stage of proof. Comparative studies show the robot is feasible, with reduced blood loss and similar lymph node harvests, but large-scale randomized evidence is still limited, and ongoing East Asian trials are expected to clarify its place in treatment guidelines.

Behind the trial results lies a distinctive culture of collaboration and knowledge sharing. Japanese, Korean, and Chinese surgical groups have long exchanged operative videos, built consensus documents, and performed live demonstration surgeries for international audiences. When Uyama shared detailed videos of laparoscopic D2 dissections, the clarity and sophistication of the technique astonished viewers and accelerated global understanding of what minimally invasive cancer surgery could achieve. International teleconferences and live surgical transmissions, including real-time dialogue between operating surgeons and remote experts, have proven educational even for highly experienced operators. The review argues that this openness is not incidental but essential: meaningful innovation in surgery depends on institutions and countries actively sharing what works, what fails, and how standards can be harmonized across centers with very different case volumes and resources.

The review also emphasizes that surgeons themselves should drive the technology, not merely adopt it. The author describes identifying the limitations of conventional two-dimensional endoscopic visualization, particularly in depth perception and structural recognition, and then collaborating with engineering teams to develop three-dimensional laparoscopic endoscopes that improved precision in dissection and reconstruction. This surgeon-inventor model, the argument goes, should be cultivated from the earliest stages of surgical education, because only clinicians embedded in daily operative reality can identify the design flaws that matter for safety and outcomes. The same philosophy extends to how new techniques spread. Simple publication is not enough. The safest dissemination strategy embeds innovation within clinical trials that include structured quality assurance: objective assessment of surgical proficiency, standardized operative guidelines, procedure manuals, educational videos, and validated evaluation forms.

As standard procedures mature, attention has turned to optimization and personalization. Reconstruction after proximal gastrectomy has become a fertile arena for innovation. The SPADE technique uses double-suture anchoring between the posterior wall of the esophagus and the anterior wall of the stomach to create a flap and pseudo-fornix, improving anti-reflux function and reducing complications. The OFFROAD technique reinforces anastomoses and dissected areas with remaining omental tissue, and preliminary studies suggest it does not significantly increase operative time or complication rates while potentially mitigating the severity of leaks. The ongoing ADDICT trial is asking a more fundamental question: whether D1+ or D2 dissection is the appropriate extent for advanced gastric cancer. Meanwhile, function-preserving approaches are challenging the assumption that every early cancer needs the same resection as advanced disease. Middle segmental gastrectomy, an evolution of pylorus-preserving gastrectomy, aims to maintain gastric function for tumors in the middle third of the stomach, and sentinel node navigation surgery, inspired by melanoma trials and refined by the SENORITA group, may allow less extensive resections in carefully selected patients based on biologic information from mapped lymphatic basins.

Optimization now begins well before the operating room. The review highlights anemia as one of the most important modifiable preoperative factors, since suboptimal hemoglobin worsens recovery, raises complication rates, and harms long-term outcomes. A seven-year multicenter trial demonstrated that intravenous ferric carboxymaltose significantly improves hemoglobin levels and reduces transfusion needs in surgical patients. In parallel, patient blood management, endorsed by the World Health Organization, promotes evidence-based transfusion thresholds, meticulous intraoperative hemostasis, and preservation of the patient’s own blood, with benefits including faster recovery, shorter hospital stays, and fewer transfusion-related risks. These strategies reflect a broader shift toward holistic, patient-centered care in which surgical technique, perioperative medicine, and long-term survivorship are planned together rather than treated as separate phases.

The most consequential frontier, however, is artificial intelligence. Deep-learning systems for endoscopy have already demonstrated improved detection rates of early gastric cancer lesions, reducing operator-dependent variability and potentially enabling earlier diagnosis. Computer vision models are being trained to recognize surgical phases, identify critical structures such as lymph node stations, major vessels, and dissection planes, and provide real-time feedback during laparoscopic and robotic gastrectomy. Machine learning algorithms integrating clinical, laboratory, and imaging data show promise for predicting survival and postoperative complications, supporting individualized prehabilitation and risk stratification. Yet the review is candid about the obstacles. Many AI applications rest on small, single-center datasets with limited external validation, and concerns about data privacy, algorithmic interpretability, medico-legal responsibility, and workflow integration remain unresolved. Autonomous robotic systems, despite demonstrating remarkable precision in experimental tasks, remain far from safe independent deployment in complex oncologic surgery, where judgment and ethical responsibility remain fundamentally human.

The future envisioned is collaborative rather than substitutive. Flexible robotic platforms such as K-Flex, holographic and three-dimensional printed preoperative modeling, and the coming flood of genomic, proteomic, and radiomic data will give surgeons tools of unprecedented power, but translating that data into actionable treatment decisions, from the choice and extent of surgery to perioperative therapy and surveillance, will require clinicians who are curious, data-driven, and committed to patient safety. In the model the review proposes, AI assists with case selection, operative planning, intraoperative guidance, and postoperative monitoring, while surgeons interpret the unexpected, weigh patient values, and take responsibility for nuanced decisions. Global capacity-building through tele-mentoring, simulation, and structured fellowships is meant to ensure these advances reach patients far beyond the high-volume East Asian centers where they were born. The transformation of gastric cancer surgery, from Billroth’s open incisions to intelligent operating rooms, is ultimately a story about surgeons who refused to stop asking whether the operation could be done better, and who built the evidence, the tools, and the networks to find out.

Subject of Research: Evolution and future of minimally invasive gastric cancer surgery, including randomized trial evidence, surgical innovation, and artificial intelligence applications

Article Title: Innovations in Gastric Cancer Surgery During Early Minimally Invasive Era and Future Perspectives

Article References: El‐On, R., & Kim, Y.-W. (2026). Innovations in Gastric Cancer Surgery During Early Minimally Invasive Era and Future Perspectives. Annals of Gastroenterological Surgery, 10(5), 1382-1387. https://doi.org/10.1002/ags3.70234

Image Credits: AI Generated

DOI: 10.1002/ags3.70234

Keywords: gastric cancer, laparoscopic gastrectomy, D2 lymphadenectomy, robotic surgery, randomized controlled trials, artificial intelligence, sentinel node navigation, function-preserving surgery, patient blood management, surgical innovation, minimally invasive surgery, East Asia